While back to school can be lots of fun, it can also mean back to lots of viruses! RSV season is coming and this year, we may have an extra tool to help protect our littlest patients from severe symptoms caused by RSV.
RSV, which stands for respiratory syncytial virus, is a common respiratory virus that can infect people of all ages. For most people, it causes mild cold-like symptoms. However, babies have small, delicate airways which makes them more susceptible to severe symptoms with RSV. Infants less than 6 months old, premature infants, and infants with other health conditions such as chronic lung disease are especially at increased risk of developing difficulty breathing when infected with RSV.
The good news is that as of this summer, the FDA approved a new monoclonal antibody shot (nirsevimab, brand name BeyfortusTM) to help prevent severe disease from RSV. The CDC and American Academy of Pediatrics then published their recommendations that all infants 8 months and under receive one dose of nirsevimab when entering their first RSV season. It is also recommended for some children aged 8 to 19 months if they are entering their second RSV season and have certain risk factors.
The RSV monoclonal antibody shot works by providing passive immunity to RSV, meaning it gives your baby’s immune system extra help in fighting off the virus. It can significantly reduce the risk of severe infection and hospitalization, and it is a safe and effective way to help keep your little ones safe this winter.
Our practice is working hard to get the shot as soon as it is available for distribution. Stay tuned for updates!